Introducing patient-centric SARS-CoV-2 serology testing with Trajan Scientific and Medical and Synexa Life Sciences

Introducing patient-centric SARS-CoV-2 serology testing with Trajan Scientific and Medical and Synexa Life Sciences

February 17, 2021

In response to the COVID-19 pandemic, the biopharmaceutical industry has leapt into action to better understand the disease and develop suitable vaccines and therapies. Trajan Scientific and Medical and Synexa Life Sciences have developed and validated an innovative, market-leading SARS-CoV-2 serology assay, available for high-throughput clinical research applications, using Trajan's advanced precision microsampling technology to expedite therapy and vaccine development as well as large-scale screening, sero-surveillance and post-market surveillance initiatives.

With hemaPEN’s® innovative, easy-to-use design and microsampling technology, large scale screening and sero-surveillance studies post-vaccine roll out can be conducted safely and efficiently, while maintaining social distancing protocols and maintaining patient-centricity, comfort and convenience.

Combining this technology with Synexa’s innovative, market-leading SARS-CoV-2 serology assay - a versatile technology capable of detecting IgG, IgM, IgA and nAb antibody response, as well as their semi-quantification without the need for titration - has yielded a highly competitive and flexible assay, suitable across a wide range of applications.

Through this collaboration, Trajan and Synexa have developed a powerful platform to enable vaccine programs with more convenience and comfort for the patient, while retaining high quality data for understanding the safety and efficacy of vaccines.

If you would like more information about our product and service offering to assist and support your vaccine program, please contact us.

Download
Brochure - SARS-CoV-2 serology testing

Related news
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC's Analyst

More information
www.hemapen.com

Media contact information
Trajan Scientific and Medical
Tel: +44 (0) 1908 568 844
media@trajanscimed.com




Also in News

Trajan Scientific and Medical continues its focus on Microsampling
Trajan Scientific and Medical continues its focus on Microsampling

April 20, 2022

Trajan Scientific and Medical, (Trajan, ASX:TRJ) partnered with researchers at The University of Queensland to develop a skin microbiopsy device which takes tissue samples smaller than 0.5mm in diameter.  It can be used to collect biopsies for skin conditions, including skin cancers.

Read More

Cathy Cordova Appointed Trajan's General Manager of Microsampling Unit
Cathy Cordova Appointed Trajan's General Manager of Microsampling Unit

February 16, 2022

Cathy Cordova has been appointed the General Manager of the consolidated Microsampling Business Unit for Trajan Scientific and Medical.

Read More

Dr Xumei Gao (Bryan) awarded REDI fellowship to partner with Trajan.
Dr Xumei Gao (Bryan) awarded REDI fellowship to partner with Trajan.

January 27, 2022

 Dr Xumei Gao (Bryan) a Postdoctoral Researcher from the ARC Training Centre for Personalized Therapeutics Technologies at the University of Melbourne, has been awarded a REDI fellowship to partner with Trajan.

Read More